Chemometec's newest cell analysis instrument, which was launched in January, spearheads the company's all-important strategy to deliver instruments to biotech companies involved in cell therapy. Analyst points out the company as a potential acquisition target.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.